A5102945730- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Venous Thromboembolism Diagnosis and Management
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Gut microbiota and health
- Bone health and treatments
- Immune Cell Function and Interaction
- Anesthesia and Sedative Agents
- Vitamin C and Antioxidants Research
- Medical Imaging and Pathology Studies
- Metastasis and carcinoma case studies
- Immune cells in cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Intensive Care Unit Cognitive Disorders
Moores Cancer Center
2019-2025
University of California, San Diego
2019-2025
The Ohio State University
2018-2023
Adena Health System
2023
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2018-2022
University of Florida
2020-2021
UC San Diego Health System
2021
Massachusetts General Hospital
2020
Mount Sinai Medical Center
2013
Los Angeles Medical Center
2010
The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed ligand (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, their development is associated with improved patient survival across tumor types. impact on for patients non-small lung cancer (NSCLC) who develop multisystem irAEs ICIs, not described.To characterize irAEs, association survival, risk factors irAE development.This retrospective cohort study...
Abstract Background The microbiome has been shown to affect the response Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and preclinical models. Here, we sought broadly survey identify those which may play prognostic role using retrospective analyses patients with advanced cancer treated ICIs. Methods We conducted analysis 690 who received ICI therapy for cancer. used literature review define causal model relationship between medications, microbiome, guide abstraction...
Cancer cachexia exhibits decreased albumin and associates with short overall survival (OS) in patients non-small cell lung cancer (NSCLC), but whether on-treatment changes associate OS NSCLC treated immune checkpoint inhibitors (ICIs) combination chemoimmunotherapy has not been thoroughly evaluated.
Abstract Introduction: While circulating tumor DNA-based tests have shown promise in evaluating treatment response, predicting prognosis, and detecting measurable residual disease, tumor-informed personalized strategies limitations. For example, the need for large samples complexity high cost of testing can be barriers to clinical use. Commercially available genomic methylation tumor-independent assays require panels sample splitting, further limiting their practicality. Both these sent...
Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data available regarding either risk of irTCP or the effect on clinical outcomes patients treated ICI.We conducted a retrospective review sequential cancer ICI between 2011 2017 at our institution. All who received alone in combination other systemic therapy any line treatment were included;...
Background Some cancer patients who are diagnosed with thromboembolism may require dual treatment vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and Xa (low‐molecular‐weight heparin [LMWH] or direct oral anticoagulants [DOACs]). However, to the authors' knowledge, safety of such combinations has not been well characterized. Methods Patients advanced were treated concurrent VEGFR TKIs between 2010 2018 at The Ohio State University Comprehensive Cancer...
Background and Purpose: The display resolution of the Apple iPad? is 1024 × 768 pixels, which greater than that required for generating typical CT or MRI images. purpose this study to determine if specific MR sequences can be interpreted accurately on mobile device/PACS software platforms when compared a traditional stationary high monitor/PACS radiological workstation. If so, allows radiologists provide comparable interpretation as they were onsite at an imaging center hospital. Materials...
94 Background: The response to Immunotherapy (IO) is known be affected by concomitant medications including corticosteroids and antibiotics. We evaluated the medication history of patients undergoing IO explore other that affect overall survival estimate relative impact each when given in combination. Methods: A retrospective review with advanced cancer who received from 2011 2017 at Ohio State University was performed IRB approval. Data were extracted medical record, 180 days around start...
e20639 Background: The addition of IO to chemotherapy for first-line treatment SCLC has improved median overall survival (OS). No OS difference was observed in patients with brain metastases the clinical trial setting, however outcomes need be assessed non-clinical setting. Methods: This retrospective study included 121 who received ICI-based therapy between 2016-2022 at Ohio State University. Medical records were extracted via chart review and data collected REDCap. Clinical characteristics...